Published in N Engl J Med on November 14, 2010
Eplerenone in Heart Failure Treatment (INOSET) | NCT02344199
Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. Am J Med (2013) 3.46
Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nat Med (2012) 2.59
Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ (2015) 2.40
Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes. Kidney Int (2014) 2.22
Estrogen receptor inhibits mineralocorticoid receptor transcriptional regulatory function. Endocrinology (2014) 2.17
Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol (2014) 2.13
Mobile phone-based telemonitoring for heart failure management: a randomized controlled trial. J Med Internet Res (2012) 2.06
Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in Duchenne muscular dystrophy mice. Circulation (2011) 2.06
Spironolactone use and higher hospital readmission for Medicare beneficiaries with heart failure, left ventricular ejection fraction <45%, and estimated glomerular filtration rate <45 ml/min/1.73 m(2.). Am J Cardiol (2014) 2.02
De novo acute heart failure and acutely decompensated chronic heart failure. Dtsch Arztebl Int (2015) 1.93
Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide. J Am Coll Cardiol (2012) 1.66
Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail (2012) 1.62
Smooth muscle cell mineralocorticoid receptors are mandatory for aldosterone-salt to induce vascular stiffness. Hypertension (2013) 1.59
Contemporary cardiac issues in Duchenne muscular dystrophy. Working Group of the National Heart, Lung, and Blood Institute in collaboration with Parent Project Muscular Dystrophy. Circulation (2015) 1.55
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J (2016) 1.52
Effects of Beta-Blocker Withdrawal in Acute Decompensated Heart Failure: A Systematic Review and Meta-Analysis. JACC Heart Fail (2015) 1.48
Perceptions and experiences of heart failure patients and clinicians on the use of mobile phone-based telemonitoring. J Med Internet Res (2012) 1.48
Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial. Eur Heart J (2013) 1.47
Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J (2015) 1.46
Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail (2015) 1.42
Cardiac microinjury measured by troponin T predicts collagen metabolism in adults aged >=65 years with heart failure. Circ Heart Fail (2012) 1.39
Fool's gold, lost treasures, and the randomized clinical trial. BMC Cancer (2013) 1.39
[Summary of the article: Zannad F, McMurray JJV, Krum H et al.; for the EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med, 2011; 364: 11-21]. Kardiol Pol (2011) 1.39
Mineralocorticoid receptors in vascular function and disease. Mol Cell Endocrinol (2011) 1.38
Experimental mild renal insufficiency mediates early cardiac apoptosis, fibrosis, and diastolic dysfunction: a kidney-heart connection. Am J Physiol Regul Integr Comp Physiol (2011) 1.24
Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat Rev Nephrol (2013) 1.22
The Renin-Angiotensin-aldosterone system in vascular inflammation and remodeling. Int J Inflam (2014) 1.13
Metabolic rates of ATP transfer through creatine kinase (CK Flux) predict clinical heart failure events and death. Sci Transl Med (2013) 1.08
Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. Eur J Heart Fail (2013) 1.06
Biomarkers: optimizing treatment guidance in heart failure. Clin Res Cardiol (2011) 1.05
Quantification of cardiomyocyte hypertrophy by cardiac magnetic resonance: implications for early cardiac remodeling. Circulation (2013) 1.05
Aldosterone promotes vascular remodeling by direct effects on smooth muscle cell mineralocorticoid receptors. Arterioscler Thromb Vasc Biol (2013) 1.04
Plasma aldosterone levels are elevated in patients with pulmonary arterial hypertension in the absence of left ventricular heart failure: a pilot study. Eur J Heart Fail (2012) 1.04
Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions. Heart Fail Rev (2014) 1.03
Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure. Circ Heart Fail (2013) 1.02
Mineralocorticoid receptors in immune cells: emerging role in cardiovascular disease. Steroids (2014) 1.01
Role of Rac1-mineralocorticoid-receptor signalling in renal and cardiac disease. Nat Rev Nephrol (2013) 1.01
Sex and gender differences in myocarditis and dilated cardiomyopathy. Curr Probl Cardiol (2013) 1.01
The relationship between serum markers of collagen turnover and cardiovascular outcome in the elderly: the Cardiovascular Health Study. Circ Heart Fail (2011) 0.99
Contemporary strategies in the diagnosis and management of heart failure. Mayo Clin Proc (2014) 0.98
Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail (2014) 0.98
Cystatin C identifies patients with stable chronic heart failure at increased risk for adverse cardiovascular events. Circ Heart Fail (2012) 0.97
Mechanical unloading promotes myocardial energy recovery in human heart failure. Circ Cardiovasc Genet (2014) 0.97
Iron deficiency in community-dwelling US adults with self-reported heart failure in the National Health and Nutrition Examination Survey III: prevalence and associations with anemia and inflammation. Circ Heart Fail (2011) 0.97
Renal dysfunction in acute and chronic heart failure: prevalence, incidence and prognosis. Heart Fail Rev (2012) 0.96
Targeting the renin-angiotensin-aldosterone system in heart failure. Nat Rev Cardiol (2013) 0.95
Hospitalist and primary care physician perspectives on medication management of chronic conditions for hospitalized patients. J Hosp Med (2014) 0.95
The REFER (REFer for EchocaRdiogram) protocol: a prospective validation of a clinical decision rule, NT-proBNP, or their combination, in the diagnosis of heart failure in primary care. Rationale and design. BMC Cardiovasc Disord (2012) 0.93
Myocardial extracellular volume by cardiac magnetic resonance imaging in patients treated with anthracycline-based chemotherapy. Am J Cardiol (2012) 0.92
Recent trends in the characteristics and prognosis of patients hospitalized with acute heart failure. Clin Epidemiol (2011) 0.91
Mode of death on Chagas heart disease: comparison with other etiologies. a subanalysis of the REMADHE prospective trial. PLoS Negl Trop Dis (2013) 0.91
Mineralocorticoid receptors in vascular disease: connecting molecular pathways to clinical implications. Curr Atheroscler Rep (2013) 0.90
Additional use of an aldosterone antagonist in patients with mild to moderate chronic heart failure: a systematic review and meta-analysis. Br J Clin Pharmacol (2013) 0.90
Pathological ventricular remodeling: therapies: part 2 of 2. Circulation (2013) 0.90
Chronic heart failure in older adults. Med Clin North Am (2011) 0.90
The past, present and future of renin-angiotensin aldosterone system inhibition. Int J Cardiol (2012) 0.90
Cost-effectiveness of heart failure therapies. Nat Rev Cardiol (2013) 0.89
Heart failure in East Asia. Curr Cardiol Rev (2013) 0.89
Aldosterone receptor antagonists: current perspectives and therapies. Vasc Health Risk Manag (2013) 0.88
Aldosterone antagonists in systolic heart failure. Can Fam Physician (2014) 0.88
Discovery and in Vivo Evaluation of Potent Dual CYP11B2 (Aldosterone Synthase) and CYP11B1 Inhibitors. ACS Med Chem Lett (2013) 0.88
Endothelial Mineralocorticoid Receptors Differentially Contribute to Coronary and Mesenteric Vascular Function Without Modulating Blood Pressure. Hypertension (2015) 0.88
The hypertension of Cushing's syndrome: controversies in the pathophysiology and focus on cardiovascular complications. J Hypertens (2015) 0.88
Comparative effectiveness research in heart failure therapies: women, elderly patients, and patients with kidney disease. Heart Fail Clin (2012) 0.87
The mineralocorticoid receptor promotes fibrotic remodeling in atrial fibrillation. J Biol Chem (2014) 0.87
Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy. Clin J Am Soc Nephrol (2014) 0.87
The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. Clin Sci (Lond) (2016) 0.87
Consistency of Laboratory Monitoring During Initiation of Mineralocorticoid Receptor Antagonist Therapy in Patients With Heart Failure. JAMA (2015) 0.86
Long-term effects of spironolactone in peritoneal dialysis patients. J Am Soc Nephrol (2013) 0.86
Trends in the medical management of patients with heart failure. J Clin Med Res (2013) 0.86
Atrial fibrillation in heart failure: what should we do? Eur Heart J (2015) 0.86
A randomized pilot study of aortic waveform guided therapy in chronic heart failure. J Am Heart Assoc (2014) 0.86
Smooth muscle cell mineralocorticoid receptors: role in vascular function and contribution to cardiovascular disease. Pflugers Arch (2013) 0.86
The multifaceted mineralocorticoid receptor. Compr Physiol (2014) 0.85
Aldosterone and vascular mineralocorticoid receptors: regulators of ion channels beyond the kidney. Hypertension (2013) 0.85
Role of mineralocorticoid receptor antagonists in cardiovascular disease. Circ Res (2015) 0.85
Apocynin attenuates oxidative stress and cardiac fibrosis in angiotensin II-induced cardiac diastolic dysfunction in mice. Acta Pharmacol Sin (2013) 0.85
The ubiquitous mineralocorticoid receptor: clinical implications. Curr Hypertens Rep (2012) 0.85
Temporal Trends and Hospital Variation in Mineralocorticoid Receptor Antagonist Use in Veterans Discharged With Heart Failure. J Am Heart Assoc (2015) 0.85
Aldosterone, mineralocorticoid receptor activation, and cardiovascular remodeling. Circulation (2011) 0.84
Different Somatic Mutations in Multinodular Adrenals With Aldosterone-Producing Adenoma. Hypertension (2015) 0.84
Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF). Eur J Heart Fail (2013) 0.84
PDE3 inhibition in dilated cardiomyopathy. Curr Opin Pharmacol (2011) 0.84
New medical therapies for heart failure. Nat Rev Cardiol (2015) 0.83
Devices in the management of advanced, chronic heart failure. Nat Rev Cardiol (2012) 0.83
Sex-related differences in patients' responses to heart failure therapy. Nat Rev Cardiol (2012) 0.83
[Not Available]. Rev Clin Esp (2011) 0.83
Loop diuretics in heart failure. Heart Fail Rev (2012) 0.83
Registry in Germany focusing on level-specific and evidence-based decision finding in the treatment of heart failure: REFLECT-HF. Clin Res Cardiol (2014) 0.82
Is dietary sodium policy actually based on science? Adv Nutr (2015) 0.82
The diuretic torasemide does not prevent aldosterone-mediated mineralocorticoid receptor activation in cardiomyocytes. PLoS One (2013) 0.82
The 2012-2013 Canadian Hypertension Education Program (CHEP) guidelines for pharmacists: An update. Can Pharm J (Ott) (2013) 0.82
Aldosterone and cardiovascular disease: the heart of the matter. Trends Endocrinol Metab (2012) 0.82
Hotline update of clinical trials and registries presented at the at the European Society of Cardiology Congress in Paris 2011. Clin Res Cardiol (2011) 0.81
Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms. Heart (2014) 0.81
Current treatment of heart failure with preserved ejection fraction: should we add life to the remaining years or add years to the remaining life? Cardiol Res Pract (2013) 0.81
Hyperkalemia among hospitalized patients and association between duration of hyperkalemia and outcomes. Arch Med Sci (2014) 0.81
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet (2007) 20.57
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med (1991) 16.19
Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med (2011) 15.70
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ (2007) 14.52
Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet (2010) 14.40
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol (2008) 14.36
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med (2009) 14.13
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med (2005) 12.46
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 11.88
Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA (2006) 11.87
Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med (2014) 11.77
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med (2008) 11.61
Guidelines on the management of valvular heart disease (version 2012). Eur Heart J (2012) 10.70
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med (2003) 10.57
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med (2007) 10.43
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation (2013) 10.07
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet (2003) 9.98
Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med (2012) 9.46
Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med (2004) 9.13
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med (2007) 8.77
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet (2009) 8.54
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med (2007) 8.46
Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA (2002) 8.28
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet (2003) 8.12
Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med (2012) 7.93
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med (2007) 7.87
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. N Engl J Med (2007) 7.86
Rosuvastatin in older patients with systolic heart failure. N Engl J Med (2007) 7.55
Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med (2013) 7.35
Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation (2002) 7.25
A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. N Engl J Med (2004) 7.08
Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet (2007) 6.88
Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med (2005) 6.86
Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet (2012) 6.69
The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation (2006) 6.58
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA (2007) 6.25
Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis. Psychosom Med (2004) 6.00
Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med (2014) 5.93
Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med (2008) 5.86
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology (2007) 5.77
A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med (2002) 5.55
Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg (2012) 5.49
Bivalirudin for patients with acute coronary syndromes. N Engl J Med (2006) 5.49
Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med (2010) 5.48
Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 5.46
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Bull World Health Organ (2007) 5.38
Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med (2007) 5.37
Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med (2009) 5.34
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Epidemiology (2007) 5.12
Contribution of SHANK3 mutations to autism spectrum disorder. Am J Hum Genet (2007) 5.04
Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol (2007) 4.74
Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA (2012) 4.73
Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med (2013) 4.67
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med (2015) 4.56
B-type natriuretic peptide-guided heart failure therapy: A meta-analysis. Arch Intern Med (2010) 4.42
Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 4.38
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA (2007) 4.30
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Prev Med (2007) 4.29
Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol (2007) 4.19
Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials. JAMA (2012) 4.13
Strategy for intention to treat analysis in randomised trials with missing outcome data. BMJ (2011) 4.12
Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail (2010) 3.90
Identification of seven loci affecting mean telomere length and their association with disease. Nat Genet (2013) 3.87
2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation (2013) 3.86
Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation (2006) 3.85
Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk. N Engl J Med (2015) 3.81
Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet (2005) 3.67
Vascular complications associated with arteriotomy closure devices in patients undergoing percutaneous coronary procedures: a meta-analysis. J Am Coll Cardiol (2004) 3.67
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet (2012) 3.66
Decreasing one-year mortality and hospitalization rates for heart failure in Sweden; Data from the Swedish Hospital Discharge Registry 1988 to 2000. Eur Heart J (2004) 3.65
Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol (2004) 3.58